Stay updated on Nivolumab Plus Ipilimumab in Salivary Gland Cancer Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Salivary Gland Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Plus Ipilimumab in Salivary Gland Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' on the webpage has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change likely indicates a modification in the specific criteria that researchers are seeking in participants for the clinical trial.
    Difference
    52%
    Check dated 2024-05-22T07:44:08.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value on the webpage related to a study on Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer has been updated from 2023 to 2024. This change likely signifies a recent update or revision in the study timeline or information.
    Difference
    1%
    Check dated 2024-05-07T12:49:50.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:14:12.000Z thumbnail image

Stay in the know with updates to Nivolumab Plus Ipilimumab in Salivary Gland Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Salivary Gland Cancer Clinical Trial page.